Compare RDW & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | DAWN |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | 750 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | RDW | DAWN |
|---|---|---|
| Price | $9.27 | $12.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $12.83 | ★ $27.11 |
| AVG Volume (30 Days) | ★ 15.6M | 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $38.80 | $53.52 |
| Revenue Next Year | $17.95 | $27.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $4.87 | $5.64 |
| 52 Week High | $22.25 | $13.20 |
| Indicator | RDW | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 61.59 |
| Support Level | $7.05 | $6.40 |
| Resistance Level | $10.06 | $13.20 |
| Average True Range (ATR) | 0.81 | 0.79 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 59.83 | 91.75 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.